Skip to Main Content (Press Enter)

Logo UNISR
  • ×
  • Home
  • People
  • Outputs
  • Organizations
  • Expertise & Skills
  • Equipment

UNIFIND
Logo UNISR

|

UNIFIND

unisr.it
  • ×
  • Home
  • People
  • Outputs
  • Organizations
  • Expertise & Skills
  • Equipment
  1. Outputs

Beyond First-Line Immunotherapy: Potential Therapeutic Strategies Based on Different Pattern Progressions: Oligo and Systemic Progression

Academic Article
Publication Date:
2021
Short description:
Beyond First-Line Immunotherapy: Potential Therapeutic Strategies Based on Different Pattern Progressions: Oligo and Systemic Progression / Prelaj, A., Pircher Chiara, C., Massa, G., Martelli, V., Corrao, G., Lo Russo, G., Proto, C., Ferrara, R., Galli, G., De Toma, A., Genova, C., Jereczek-Fossa Barbara, A., Braud Filippo, D.e., Garassino Marina, C., Rebuzzi Sara, E.. - In: CANCERS. - ISSN 2072-6694. - 9:5(2021), pp. 1143-1161. [10.3390/cancers13061300]
abstract:
First-line immune-checkpoint inhibitor (ICI)-based therapy has deeply changed the treatment landscape and prognosis in advanced non-small cell lung cancer (aNSCLC) patients with no targetable alterations. Nonetheless, a percentage of patients progressed on ICI as monotherapy or combinations. Open questions remain on patients' selection, the identification of biomarkers of primary resistance to immunotherapy and the treatment strategies to overcome secondary resistance to first-line immunotherapy. Local ablative approaches are the main therapeutic strategies in oligoprogressive disease, and their role is emerging in patients treated with immunotherapy. Many therapeutic strategies can be adapted in aNSCLC patients with systemic progression to personalize the treatment approach according to re-characterization of the tumors, previous ICI response, and type of progression. This review's aim is to highlight and discuss the current and potential therapeutic approaches beyond first-line ICI-based therapy in aNSCLC patients based on the pattern of disease progression (oligoprogression versus systemic progression).
Iris type:
1.1.3. Articolo in Rivista - Comment, Editorial, Note, Reply
List of contributors:
Prelaj, Arsela; Pircher Chiara, Carlotta; Massa, Giacomo; Martelli, Valentino; Corrao, Giulia; Lo Russo, Giuseppe; Proto, Claudia; Ferrara, R; Galli, Giulia; De Toma, Alessandro; Genova, Carlo; Jereczek-Fossa Barbara, Alicja; Braud Filippo, De; Garassino Marina, Chiara; Rebuzzi Sara, Elena
Authors of the University:
FERRARA ROBERTO
Handle:
https://iris.unisr.it/handle/20.500.11768/176418
Published in:
CANCERS
Journal
  • Use of cookies

Powered by VIVO | Designed by Cineca | 26.11.1.0